Tags

high-risk localized prostate cancer

Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy: Beyond the Abstract
High-risk localized prostate cancer is a highly heterogeneous disease from a clinical and biological standpoint. It carries a significant chance of morbidity and mortality. The 2015 National Comprehensive Cancer Network (NCCN) guidelines define high-risk prostate cancer as a biopsy Gleason score of 8–10, a PSA level greater than 20 ng/mL, or clinical stage T3a disease. Despite the impact of PSA screening on improves outcome of men with prostate cancer, a significant proportion of men continue to present with high risk disease and need optimal treatment.

Published August 15, 2017
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
BACKGROUND:

In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics.

Published July 5, 2017

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Tags

high-risk localized prostate cancer

Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy: Beyond the Abstract

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Free Daily and Weekly newsletters offered by content of interest

Login